中级和低风险的先进或转移性清细胞细胞癌的第一线治疗
Michael T Serzan1, Wenxin Xu1, Stephanie A Berg1
1Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street D1230, Boston, MA 02115, USA.
Hematology/oncology clinics of North America
|May 31, 2023
概括
与免疫检查点阻断剂的组合疗法改善了与单一治疗sunitinib相比,针对特定风险群体的患者的治疗结果. 未来的试验将探索适应性策略,三重疗法和生物标志物,以获得最佳的预先治疗选择.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 临床试验 临床试验
背景情况:
- 苏尼蒂尼布单一治疗是某些癌症类型的标准治疗方法.
- 免疫检查点阻断剂 (ICB) 已成为一个有前途的治疗策略.
- 确定最佳的前期治疗对于改善患者的生存率至关重要.
研究的目的:
- 为了评估组合疗法的疗效与sunitinib单一疗法的疗效.
- 为了确定从组合治疗中获益最多的患者子组.
- 为预先癌症治疗的未来临床试验设计提供信息.
主要方法:
- 综合疗法 (ICBs) 与单疗法sunitinib的比较分析.
- 专注于中等和低风险患者子组.
- 总体应答率,无进展生存率和总体生存率数据的审查.
主要成果:
- 与sunitinib相比,组合疗法显示出更高的整体响应率.
- 随着组合治疗,观察到更好的无进展生存期.
- 在接受组合治疗的患者中,观察到总体存活率的提高.
结论:
- 与免疫检查点阻断剂的联合疗法在中等和低风险患者中,比单独治疗sunitinib有显著的生存益处.
- 未来的研究应该专注于适应性临床试验设计,探索三重方案,并确定新的生物标志物.
- 基于风险分层和生物标志物的个性化治疗选择对于优化癌症护理至关重要.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Chronic Kidney Disease III: Interprofessional Care
51
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
51
Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Continuous Renal Replacement Therapy
56
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
56
Renal Drug Clearance: Overview
256
Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
256


